
The Readout Loud
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Sep 26, 2024
Jonathan Wosen, a seasoned colleague in oncology research, shares insights on the latest shifts in the life sciences. The conversation highlights Genentech's decision to close its cancer immunology division and the reaction from the biotech community. Wosen also discusses Pfizer’s withdrawal of its sickle cell treatment and the implications for future drug approvals. Additionally, they explore the promising prospects of a new schizophrenia drug set to be approved, emphasizing the urgent need for innovative therapies in mental health.
32:02
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Pfizer's withdrawal of its sickle cell drug highlights critical safety concerns and reflects the industry's ongoing challenges with accelerated approval processes.
- The anticipated approval of Bristol-Myers Squibb's CAR XT for schizophrenia signifies a major breakthrough in treatment options for this complex disorder.
Deep dives
Pfizer's Withdrawal of Sickle Cell Drug
Pfizer's decision to withdraw its sickle cell treatment, Ox-Bryta, from global markets marks a significant development in the life sciences. Approved in both the U.S. and Europe, this drug was expected to provide relief for patients but raised safety concerns after recent findings indicated a troubling imbalance of adverse events, including fatalities. The withdrawal has raised questions about Pfizer's due diligence during its acquisition of Global Blood Therapeutics, highlighting the need for thorough evaluation of accelerated approval drugs. This surprising move reflects broader concerns within the pharmaceutical industry regarding the efficacy and safety profiles of treatments previously deemed promising.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.